





KINGSMILL

RESORT =

Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients

Khalid Shaqdan MB BCh\*, Yasir Al-Dojaily BS, Shaimaa Fadl MB BCh, Elizabeth K Proffitt MD, Frank Dana MD, Leila Rezai Gharai MD, Mark S Parker MD FACR



#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients Disclosure of Commercial Interest

#### Co-authorship Thoracic Imaging Textbooks

Lung Cancer Screening

Mark S Parker, Robert C. Groves, Joanna El Kusmirek, Leila Rezai Gharai, and Samira Shojaee; Thieme, New York; 2017


Chest Imaging Case Atlas, 2<sup>nd</sup> edition

Mark S Parker, Melissa L Rosado-de-Christenson, Gerald F Abbott; Thieme, New York; 2012




## Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients **BACKGROUND**

- COVID-19 in the US as of Aug 2022 1:
  - ~ 90 million cases reported
  - ~ > 1 million deaths
  - ~ 1.2% case fatality rate
- Acute respiratory distress syndrome (ARDS)
   Noncardiogenic pulmonary edema resulting in impaired oxygenation at the alveolar capillary level <sup>2-3</sup>
- Pathophysiology of COVID-19 ARDS (CARDS) includes direct cytopathic effects, diffuse alveolar hemorrhage and hyaline membrane, cytokine storm via IL-6 and TNF<sup>3</sup>





# Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients COVID-19 Respiratory Management Ladder



#### Low-flow $O_2$ :

Delivery through nasal cannula

#### High-flow nasal cannula (HFNC) 4-5:

- O<sub>2</sub> delivery system
- 100% humidified and heated oxygen
- up to 60 L/min O<sub>2</sub> through large-bore nasal cannula

#### Invasive mechanical ventilation (IMV) 4-5:

Endotracheal intubation, highest level of respiratory / ventilatory support



# Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients **Ventilator-Induced Lung Injury (VILI) - Barotrauma**

- Alveolar injury: overdistension of the lungs from mismatch between ventilatory parameters and alveolar tolerance → pneumothorax, pneumomediastinum, pneumopericardium, subcutaneous air, pneumoperitoneum <sup>6</sup>
- Ventilatory settings respiratory rate, tidal volume, positive end expiratory pressure <sup>6</sup>
- Reported barotrauma for all cause hospitalized ARDS is 4.8-11% (with ARDSnet protocol) <sup>7</sup>





### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients *Purpose of Our Study*

Investigate whether there is an increase in incidence of barotrauma in COVID-19 (+) patients requiring high flow nasal cannula (HFNC) or invasive mechanical ventilation (IMV).







## Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients Patient Selection

IRB approved, HIPPA compliant

Eligible patients (n = 514)
i. COVID-19 (+) by RT-PCR\*

ii. Hospitalization

iii. February 2020 - August 2020

• RT-PCR (reverse transcription-polymerase chain reaction)

Exclusion (n = 8)

i. Insufficient charting (n=5)

ii. COVID-19 (-) throughout hospitalization (n=2)

iii. Non-RT-PCR positive (n=1, IgG+)

Patients included in study (n = 506)

Mean Age: 52-years

250M: 256F

HFNC – High flow nasal cannula IMV – Invasive mechanical ventilation

**Control** (no resp support/low-flow O<sub>2</sub>)

n = 383

**HFNC-only** 


n = 43

**IMV** 

n = 80




#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients RESULTS - Age & Race Distribution






#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients **RESULTS - Gender Distribution**





#### RESULTS - Comorbidities and Immunosuppression



■>2 comorbid conditions ■Immunosuppression

Common comorbidities among all patients:

- Hypertension
- Diabetes mellitus type 2
- Obesity
- Hyperlipidemia
- Chronic kidney disease
- Coronary artery disease/Stroke


Immunosuppression:

- Medication-induced
- Pathological (ie. leukemia)

\* Only 1 immunosuppressed HFNC PATIENT




#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients RESULTS - Barotrauma Events



n = # of patients




#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients RESULTS – Barotrauma, Ventilator Settings and Time






## Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients RESULTS - Barotrauma and Length of Stay (LOS)



IMV patient	Barotrauma LOS (days)	No Barotrauma LOS (days)	
African- American	31	17	P<0.01
Men	46	16	P<0.001
Women	27	19	



#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients RESULTS - Mortality for IMV & HFNC




9% (45/506) died during their COVID-19 hospitalization

- 62% (28/45) were Men
- 64% (29/45) were African American
- 20% (9/45) were Caucasian

IMV GROUP	Total Mortality (n=30)	Barotrauma Mortality (n=4)	No- Barotrauma Mortality (n=26)
African- American	19/30 (63%)	3/4 (75%)	16/26 (58%)
Men	21/30 (70%)	2/4 (50%)	19/26 (73%)
Female	9/30 (30%)	2/4 (50%)	7/26 (27%)
	P<0.05		P<0.05



#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients RESULTS - Mortality for IMV & HFNC




9% (45/506) died during their COVID-19 hospitalization


HFNC group	<b>Total Mortality</b>	
African-American	3/5 (60%)	
Men	1/5 (20%)	
Female	4/5 (80%) P<0.05	






78-year-old male on IMV







57-year-old male on IMV



54-year-old female with on IMV





49-year-old male on HFNC

### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients Discussion – Barotrauma incidence

- IMV CARDS barotrauma:
  - McGuiness et al 2020 <sup>7</sup>: 15% (89/601 patients)
  - Rajdev et al. 2021 <sup>6</sup>: 17.3% (21/121 patients)
  - Steinberger et al 20228: 12% (43/363 patients)
  - Our study, comparable at 15% (12/80 patients)
  - Non-COVID ARDS barotrauma incidence (4.8-11%)<sup>7</sup>
- HFNC barotrauma:
  - Rajdev et al <sup>6</sup>: 4.7-8%
  - Our study, 1 case in 43 patients (2%)



# Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients \*Discussion - Barotrauma types\*

- Shrestha et al. 2021 <sup>9:</sup> Pneumothorax <u>72%</u> and Pneumomediastinum <u>52%</u>
- Belletti et al. 2021 <sup>10</sup>: Pneumothorax <u>78.5%</u> (chest tube needed in 18 patients; 1 required emergent thoracostomy)
- Steinberger et al 2021 8: Pneumothorax 40%
- Our study: Pneumothorax 60% and Pneumomediastinum 20%



### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients Discussion – Barotrauma and Mortality and Length of Stay

- Shrestha et al, meta-analysis of 13 studies <sup>9</sup>: average mortality of <u>58.7%</u> for hospitalized patients with COVID barotrauma vs <u>40.6%</u> mortality without barotrauma.
  - Our study, 33% mortality with barotrauma vs 38% mortality without barotrauma.
- McGuiness and Belletti et al <sup>7,10</sup>: Longer length of hospitalization and ICU admission associated with COVID-19 barotrauma
  - Our study, IMV barotrauma doubled length of hospital stay particularly in African Americans and men
- Men in the IMV group overall and African Americans in the IMV barotrauma group particularly face increased mortality.



## Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients **Conclusion**

Increased barotrauma incidence and mortality associated with IMV management of CARDS should be taken into strong consideration particularly with males, African-Americans, and in the setting of prolonged ventilation with high respiratory rate ventilator settings.



#### Incidence of Barotrauma in COVID-19 (+) Hospitalized Patients **References**

- 1. Our world in data. https://ourworldindata.org/explorers/coronavirus-data-explorer. Accessed: 4/22/2022
- 2. Johnson T, Bishoff T, Kremsreiter K et al. Diagnostic Testing for COVID-19: Systematic Review of Meta-Analyses and Evidence-Based Algorithms. Med J (Ft Sam Houst Tex). Jan-Mar 2021;(PB 8-21-01/02/03):50-59.
- 3. Swenson KE, Swenson ER. Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury. Crit Care Clin . 2021 Oct;37(4):749-776. Epub 2021 May 28.
- 4. Frat JP, Coudroy R, Marjanovic N, Thille AW. High-flow nasal oxygen therapy and noninvasive ventilation in the management of acute hypoxemic respiratory failure. Ann Transl Med. 2017 Jul; 5(14): 297.
- 5. Aslan A, Aslan C, Zolbanian NM, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia (Nathan). 2021 Dec 6;13(1):14.
- 6. Rajdev K, Spanel AJ, Mcmillan S et al. Pulmonary Barotrauma in COVID-19 Patients With ARDS on Invasive and Non-Invasive Positive Pressure Ventilation. J Intensive Care Med . 2021 Sep;36(9):1013-1017.
- 7. McGuinness G, Zhan C, Rosenberg N et al. Increased Incidence of Barotrauma in Patients with COVID-19 on Invasive Mechanical Ventilation. Radiology . 2020 Nov;297(2):E252-E262.
- 8. Steinberger S, Finkelstein M, Pagano A et al. Barotrauma in COVID 19: Incidence, pathophysiology, and effect on prognosis. Clin Imaging. 2022 Oct; 90: 71–77.
- 9. Shrestha DB, Sedhai YR, Budhathoki P et al. Pulmonary barotrauma in COVID-19: A systematic review and meta-analysis. Ann Med Surg (Lond) . 2022 Jan;73:103221.
- 10. Belletti A, Palumbo D, Zangrillo A et al. Predictors of Pneumothorax/Pneumomediastinum in Mechanically Ventilated COVID-19 Patients. J Cardiothorac Vasc Anesth . 2021 Dec;35(12):3642-3651.
- 11. Flower L, Carter JP, Lopez JR, Henry AM. Tension pneumothorax in a patient with COVID-19.

